Drug Trial Radar · NCT04211337
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
291
Actual
Start
Feb 11, 2020
Primary completion
May 22, 2023
Study completion Nov 2027
Sponsor
- Lead sponsor
- Loxo Oncology, Inc.Eli Lilly (LLY)
- Sponsor type
- Industry
- Collaborators
- Eli Lilly and Company
- First posted
- Dec 26, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.
Conditions
- Medullary Thyroid Cancer
Interventions
SelpercatinibDrug
Administered orally
CabozantinibDrug
Administered orally
VandetanibDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)Time frame: Baseline to Progressive Disease or Death from Any Cause, Whichever Occurs First, Up to 39 Months
Locations
143 sites in 20 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
City of Hope National Medical Center
Duarte, California
UCLA Hematology/Oncology - Westwood (Building 100)
Los Angeles, California
University of California Davis (UC Davis) Comprehensive Cancer Center
Sacramento, California
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California
Emory University
Atlanta, Georgia
University of Chicago Medical Center
Chicago, Illinois
Massachusetts General Hospital
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Memorial Sloan Kettering Cancer Center
New York, New York
University of Cincinnati Medical Center
Cincinnati, Ohio
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center
Columbus, Ohio
University of Pennsylvania Hospital
Philadelphia, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania
University of Texas MD Anderson Cancer Center
Houston, Texas
University of Wisconsin Hospitals and Clinics
Madison, Wisconsin
Royal North Shore Hospital
St Leonards, New South Wales, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Sir Charles Gairdner Hospital
Perth, Western Australia, Australia
Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman
Liège, Belgium
Instituto Nacional de Câncer - INCA
Rio de Janeiro, Brazil
Grupo Oncoclínicas Botafogo
Rio de Janeiro, Brazil
Grupo COI - Clínicas Oncológicas Integradas
Rio de Janeiro, Brazil
Icesp - Instituto Do Câncer Do Estado de São Paulo
São Paulo, Brazil
Centro Paulista de Oncologia Clínica
São Paulo, Brazil
Oncocentro
Belo Horizonte, Minas Gerais, Brazil
Hospital de Cancer de Londrina
Londrina, Paraná, Brazil
Hospital de Clinicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Fundação Pio XII - Hospital de Câncer de Barretos
Barretos, São Paulo, Brazil
Centro de Pesquisa Sao Lucas
Campinas, São Paulo, Brazil
Hospital de Clínicas de Ribeirão Preto
Ribeirão Preto, São Paulo, Brazil
Hospital Sírio Libanês
São Paulo, São Paulo, Brazil
Instituto D'Or de Pesquisa e Ensino (IDOR)
São Paulo, São Paulo, Brazil
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Anhui Provincial Hospital
Hefei, Anhui, China
Beijing Tongren Hospital affiliated to Capital Medical University
Beijing, Beijing Municipality, China
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
The First Affiliated Hospital Of Fujian Medical University
Fuzhou, Fujian, China
Gansu Cancer Hospital
Lanzhou, Gansu, China
Showing 40 of 143 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.